The anti-tumor effect of the powerful FASN inhibitor 3664 (TVB-3664) is related to the changes in lipid composition, including the significant reduction of FAs and phospholipids and the increase of lactoceramide and sphingomyelin in xenograft (PDX) from CRC patients sensitive to FASN inhibition, which are regulated by AMPK signaling pathway [86]. Here, FASN is linked to colorectal carcinoma.